These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30773186)

  • 1. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
    Milano MT; Katz AW; Zhang H; Huggins CF; Aujla KS; Okunieff P
    Radiother Oncol; 2019 Feb; 131():45-51. PubMed ID: 30773186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years.
    Aujla KS; Katz AW; Singh DP; Okunieff P; Milano MT
    Front Oncol; 2019; 9():111. PubMed ID: 30873385
    [No Abstract]   [Full Text] [Related]  

  • 3. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.
    Milano MT; Katz AW; Zhang H; Okunieff P
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):878-86. PubMed ID: 22172903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases.
    Soliman H; Myrehaug S; Tseng CL; Ruschin M; Hashmi A; Mainprize T; Spears J; Das S; Yang V; da Costa L; Maralani P; Heyn C; Atenafu EG; Sahgal A
    Neurosurgery; 2019 Nov; 85(5):E860-E869. PubMed ID: 31173150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
    Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
    Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
    Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
    Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases.
    Yamashita H; Niibe Y; Yamamoto T; Katsui K; Jingu K; Kanazawa S; Terahara A; Nakagawa K
    Jpn J Clin Oncol; 2016 Jul; 46(7):687-91. PubMed ID: 27162324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model.
    Diletto B; Dinapoli N; Chiesa S; Mattiucci GC; Frascino V; Anile C; Colosimo C; Valentini V; Balducci M
    Med Oncol; 2018 Sep; 35(11):146. PubMed ID: 30218407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.
    Milano MT; Katz AW; Schell MC; Philip A; Okunieff P
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1516-22. PubMed ID: 18495378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).
    Lesueur P; Lequesne J; Barraux V; Kao W; Geffrelot J; Grellard JM; Habrand JL; Emery E; Marie B; Thariat J; Stefan D
    Radiat Oncol; 2018 Jul; 13(1):138. PubMed ID: 30055640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L; Zhang XM
    J Neurosurg; 2012 Dec; 117 Suppl():49-56. PubMed ID: 23205789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.